Related Experiment Video
Updated: Jul 12, 2025

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
Pfizer BNT 162b2 COVID-19 vaccine-induced fulminant myopericarditis: A case study
Natalie L Montarello1,2, Hao Zheng Wong3, Ashlee Jeffries1
1Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Abstract:
The use of mRNA COVID-19 vaccine can on rare occasions cause life-threatening, fulminant myopericarditis. This case report demonstrates previously reported benefit of early use of venoarterial extracorporeal membrane oxygenation mechanical assistance and supports the use of intravenous highly purified immunoglobulin pharmacotherapy to help achieve a good clinical outcome.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis III: Medical Management
Pericarditis I: Introduction
Pericarditis III: Medical Management
Myocarditis IV: Nursing Management

